Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Artificial neural networks predict survival from pancreatic cancer after radical surgery.

Ansari D, Nilsson J, Andersson R, Regnér S, Tingstedt B, Andersson B.

Am J Surg. 2013 Jan;205(1):1-7. doi: 10.1016/j.amjsurg.2012.05.032.

PMID:
23245432
2.
3.

Metastatic lymph node ratio as an important prognostic factor in pancreatic ductal adenocarcinoma.

Robinson SM, Rahman A, Haugk B, French JJ, Manas DM, Jaques BC, Charnley RM, White SA.

Eur J Surg Oncol. 2012 Apr;38(4):333-9. doi: 10.1016/j.ejso.2011.12.020. Epub 2012 Feb 7.

PMID:
22317758
4.

The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer.

Riediger H, Keck T, Wellner U, zur Hausen A, Adam U, Hopt UT, Makowiec F.

J Gastrointest Surg. 2009 Jul;13(7):1337-44. doi: 10.1007/s11605-009-0919-2. Epub 2009 May 6.

PMID:
19418101
5.

Long-term survival (5-20 years) after pancreatectomy for pancreatic ductal adenocarcinoma: a series of 30 patients collected from 3 institutions.

Adham M, Jaeck D, Le Borgne J, Oussoultzouglou E, Chenard-Neu MP, Mosnier JF, Scoazec JY, Mornex F, Partensky C.

Pancreas. 2008 Nov;37(4):352-7. doi: 10.1097/MPA.0b013e31818166d2.

PMID:
18665012
6.

Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma.

Maire F, Hammel P, Terris B, Paye F, Scoazec JY, Cellier C, Barthet M, O'Toole D, Rufat P, Partensky C, Cuillerier E, Lévy P, Belghiti J, Ruszniewski P.

Gut. 2002 Nov;51(5):717-22.

7.

Follow-up after curative surgery for pancreatic ductal adenocarcinoma: asymptomatic recurrence is associated with improved survival.

Nordby T, Hugenschmidt H, Fagerland MW, Ikdahl T, Buanes T, Labori KJ.

Eur J Surg Oncol. 2013 Jun;39(6):559-66. doi: 10.1016/j.ejso.2013.02.020. Epub 2013 Mar 14.

PMID:
23498362
8.

Survival after resection for invasive intraductal papillary mucinous neoplasm and for pancreatic adenocarcinoma: a multi-institutional comparison according to American Joint Committee on Cancer Stage.

Waters JA, Schnelldorfer T, Aguilar-Saavedra JR, Chen JH, Yiannoutsos CT, Lillemoe KD, Farnell MB, Sarr MG, Schmidt CM.

J Am Coll Surg. 2011 Aug;213(2):275-83. doi: 10.1016/j.jamcollsurg.2011.04.003. Epub 2011 May 20.

PMID:
21601488
9.

Artificial neural networks--a method for prediction of survival following liver resection for colorectal cancer metastases.

Spelt L, Nilsson J, Andersson R, Andersson B.

Eur J Surg Oncol. 2013 Jun;39(6):648-54. doi: 10.1016/j.ejso.2013.02.024. Epub 2013 Mar 17.

PMID:
23514791
10.

Pancreatic resection for M1 pancreatic ductal adenocarcinoma.

Shrikhande SV, Kleeff J, Reiser C, Weitz J, Hinz U, Esposito I, Schmidt J, Friess H, Büchler MW.

Ann Surg Oncol. 2007 Jan;14(1):118-27. Epub 2006 Oct 25.

PMID:
17066229
11.

R1 resection in pancreatic cancer has significant impact on long-term outcome in standardized pathology modified for routine use.

Rau BM, Moritz K, Schuschan S, Alsfasser G, Prall F, Klar E.

Surgery. 2012 Sep;152(3 Suppl 1):S103-11. doi: 10.1016/j.surg.2012.05.015. Epub 2012 Jul 3.

PMID:
22766366
12.

Poorly differentiated resectable pancreatic cancer: is upfront resection worthwhile?

Crippa S, Partelli S, Zamboni G, Barugola G, Capelli P, Inama M, Bassi C, Pederzoli P, Falconi M.

Surgery. 2012 Sep;152(3 Suppl 1):S112-9. doi: 10.1016/j.surg.2012.05.017. Epub 2012 Jul 3.

PMID:
22766365
13.

Prognostic impact of para-aortic lymph node metastasis in pancreatic ductal adenocarcinoma.

Murakami Y, Uemura K, Sudo T, Hashimoto Y, Yuasa Y, Sueda T.

World J Surg. 2010 Aug;34(8):1900-7. doi: 10.1007/s00268-010-0577-2.

PMID:
20376442
14.

Histologic characteristics enhance predictive value of American Joint Committee on Cancer staging in resectable pancreas cancer.

Helm J, Centeno BA, Coppola D, Melis M, Lloyd M, Park JY, Chen DT, Malafa MP.

Cancer. 2009 Sep 15;115(18):4080-9. doi: 10.1002/cncr.24503.

15.

Evaluation of the prognostic factors and significance of lymph node status in invasive ductal carcinoma of the body or tail of the pancreas.

Fujita T, Nakagohri T, Gotohda N, Takahashi S, Konishi M, Kojima M, Kinoshita T.

Pancreas. 2010 Jan;39(1):e48-54. doi: 10.1097/MPA.0b013e3181bd5cfa.

PMID:
19910836
16.

Pattern of lymph node involvement and prognosis in pancreatic adenocarcinoma: direct lymph node invasion has similar survival to node-negative disease.

Pai RK, Beck AH, Mitchem J, Linehan DC, Chang DT, Norton JA, Pai RK.

Am J Surg Pathol. 2011 Feb;35(2):228-34. doi: 10.1097/PAS.0b013e318206c37a.

PMID:
21263243
17.

Role of the lymph node ratio in pancreatic ductal adenocarcinoma. Impact on patient stratification and prognosis.

La Torre M, Cavallini M, Ramacciato G, Cosenza G, Rossi Del Monte S, Nigri G, Ferri M, Mercantini P, Ziparo V.

J Surg Oncol. 2011 Nov 1;104(6):629-33. doi: 10.1002/jso.22013. Epub 2011 Jun 28.

PMID:
21713779
18.

Evaluation of surgical resection for pancreatic carcinoma at a Japanese single cancer institute.

Nanashima A, Tobinaga S, Abo T, Hatano K, Takeshita H, Nonaka T, Hidaka S, Tanaka K, Kunizaki M, Sawai T, Yasutake T, Nagayasu T.

Hepatogastroenterology. 2012 May;59(115):911-5. doi: 10.5754/hge10038.

PMID:
22469741
19.

Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma.

Chatterjee D, Katz MH, Rashid A, Wang H, Iuga AC, Varadhachary GR, Wolff RA, Lee JE, Pisters PW, Crane CH, Gomez HF, Abbruzzese JL, Fleming JB, Wang H.

Am J Surg Pathol. 2012 Mar;36(3):409-17. doi: 10.1097/PAS.0b013e31824104c5.

20.

Factors influencing outcome in patients undergoing portal vein resection for adenocarcinoma of the pancreas.

Banz VM, Croagh D, Coldham C, Tanière P, Buckels J, Isaac J, Mayer D, Muiesan P, Bramhall S, Mirza DF.

Eur J Surg Oncol. 2012 Jan;38(1):72-9. doi: 10.1016/j.ejso.2011.08.134. Epub 2011 Nov 3.

PMID:
22054617

Supplemental Content

Support Center